Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has announced the expansion of its ai² Futures Lab™ program through a new partnership with the University of Idaho College of Business and Economics, set to launch in the Spring 2026 semester. The initiative will connect student teams with real-world biopharmaceutical business development projects, providing hands-on experience in innovation, strategy, and commercialization within the life sciences sector. This collaboration underscores Apimeds’ ongoing commitment to advancing biotech innovation by empowering the next generation of leaders and entrepreneurs. By integrating academic talent with industry challenges, the program aims to bridge the gap between research and real-world application, fostering practical skills and creative problem-solving. The ai² Futures Lab™, a signature initiative of Apimeds, is designed to cultivate a pipeline of skilled professionals equipped to meet the evolving demands of the global biopharmaceutical industry. Through this partnership, students will work on projects that address key challenges in drug development, market entry, and business model innovation, all under the guidance of industry experts and university faculty. The University of Idaho’s involvement highlights the growing role of academic institutions in driving biotech advancement, particularly in regions with strong research and innovation ecosystems. The program is expected to strengthen regional economic development by supporting high-impact startups and talent retention. Apimeds continues to position itself as a leader in biopharmaceutical innovation, leveraging strategic partnerships to accelerate discovery and bring transformative therapies to patients. The expansion of the ai² Futures Lab™ marks a significant step in building a sustainable, collaborative future for the biotech industry.